Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 7
Submit an article Journal homepage
122
Views
3
CrossRef citations to date
0
Altmetric
Miscellaneous

TNF inhibition as therapy for rheumatoid arthritis

Frank A Wollheim Department of Rheumatology, Lund University Hospital, SE221 85 Lund, Sweden, E-mail: [email protected]
Pages 947-953 | Published online: 24 Feb 2005

Bibliography

  • BEUTLER B, GREENWALD D, HULMESJD et al.: Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (1985) 316(6028):552–554.
  • DAYER JM, BEUTLER B, CERAMI A: Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. Exp. Med (1985) 162(6):2163–2168.
  • ••A classic paper which paved the way forfuture work.
  • MARTIN D, NEAR SL, BENDELE A, RUSSELL DA: Inhibition of tumor necrosis factor is protective against neurologic dysfunction after active immunization of Lewis rats with myelin basic protein. Exp. Neurol (1995) 131(2):221–228.
  • [NO AUTHORS LISTED]: TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1999) 53(3):457–465.
  • ULFGREN AK, ANDERSSON U, ENGSTROM M, KLARESKOG L, MAINI RN, TAYLOR PC: Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum. (2000) 43(11):2391–2396.
  • •A novel approach towards elucidating the mechanism of action of TNF inhibition.
  • OHSHIMA S, MIMA T, SASAI M et al.: Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell deathon rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA. Cytokine (2000) 12(3):281–288.
  • •An important contribution to understanding pathogenic features of rheumatoid inflammation.
  • AGNHOLT J, KALTOFT K: Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine (2001) 15(4):212–222.
  • LUGERING A, SCHMIDT M, LUGERING N, PAUELS HG, DOMSCHKE W, KUCHARZIK T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's diseaseby using a caspase-dependent pathway. Gastroenterology (2001) 121(5):1145–1157. This paper provides direct evidence for restoration of apoptosis as an important effect of TNF inhibition.
  • TEN HOVE T, VAN MONTFRANS C, PEPPELENBOSCH MP, VAN DEVENTER SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut (2002) 50(2):206–211.
  • •This paper provides direct evidence for restoration of apoptosis as an important effect of TNF inhibition.
  • GEBOREK P, CRNKIC M, PETERSSON IF, SAXNE T: Etanercept, infliximab and leflunomide in established rheumatoid arthritis. Clinical experience using a structured follow-up programme in southern Sweden. Ann. Rheum. Dis. (2002): In press.
  • •This paper indicates that performance of TNF inhibitors in everyday practice is as good as indicated in controlled, randomised studies of RA.
  • KEMPENI J: Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody. Ann. Rheum. Dis. (2000) 59 (Suppl. 1):i44–45.
  • BARRERA P, JOOSTEN LA, DEN BROEDER AA, VAN DE PUTTE LB, VAN RIEL PL, VAN DEN BERG WB: Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann. Rheum. Dis (2001) 60(7):660–669.
  • DEN BROEDER AA, JOOSTEN LA, SAXNE T et al.: Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61(4):311–318.
  • DAVIS MW, FEIGE U, BENDELE AM, MARTIN SW, EDWARDS CK Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptorType I: a clinical update. Ann. Rheum. Dis. (2000) 59 (Suppl. 1):i41–43.
  • VAN DEN BERG WB, JOOSTEN LA, KOLLIAS G, VAN DE LOO FA: Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukinlbeta in chronicity and cartilage destruction. Ann. Rheum. Dis. (1999) 58 (Suppl. 1):I40–48.
  • DAYERJM, BRESNIHAN B: Targeting interleukin- 1 in the treatment of rheumatoid arthritis. Arthritis Rheum. (2002) 46(3):574–578.
  • COCLET-NININ J, DAYERJM, BURGER D: Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine Netw (1997) 8(4):345–349.
  • SMEETS TJ, DAYER JM, KRAAN MC et al: The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum. (2000) 43(2):270–274.
  • RONNBLOM L, ALM GV: An etiopathogenic role for the Type I IFN system in SLE. Trends Immunol (2001) 22(8):427–431.
  • ALSALAMEH S, MANGER B, KERN P, KALDEN J: New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum. (1998) 41(4):754.
  • PALMBLAD K, ERLANDSSON-HARRIS H, TRACEY KJ, ANDERSSON U: Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis : a therapeutic study using a macrophage-deactivating compound. Am. J. Pathol (2001) 158(2):491–500.
  • •An interesting new approach to modify cytokine response.
  • ATKINS MB, REDMAN B, MIER J et al.: A Phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin. Cancer Res. (2001) 7(3):486–492.
  • HARAGUCHI S, GOOD RA, CIANCIOLO GJ, JAMES-YARISH M, DAY NK: Transcriptional down-regulation of tumor necrosis factor-alpha gene expression by a synthetic peptide homologous to retroviral envelope protein." Immunol (1993) 151(5):2733–2741.
  • KOBAYASHI T, OKAMOTO K, KOBATA T, HASUMUNA T, NISHIOKA K: Apomodulation as a novel therapeutic concept for the regulation of apoptosis in rheumatoid synoviocytes. Curt: Opin. Rheumatol (1999) 11(3):188–193.
  • •A review claiming deficient apoptosis to be a major pathophysiological event in RA.
  • MASUKO-HONGO K, SAKATA M, YUAN GH et al: Expression of Fas-associated death domain-like interleukin-lbeta-converting enzyme (FLICE) inhibitory protein (FLIP) in human articular chondrocytes: possible contribution to the resistance to Fas-mediated death of M vitro cultured human articular chondrocytes. Rheumatol Int. (2001) 21(3):112–121.
  • PERLMAN H, LIU H, GEORGANAS C et al: Differential expression pattern of the antiapoptotic proteins, Bc1-2 and FLIP, in experimental arthritis. Arthritic Rheum. (2001) 44(12):2899–2908.
  • PAPADAKI HA, KRITIKOS HD, GEMETZI C et al.: Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood (2002) 99(5):1610–1619.
  • MAKAROV SS: NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritic Res. (2001) 3(4):200–206.
  • ••An excellent review of a confusing butimportant field of research.
  • EBERHARDT K, FEX E: Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br. J. Rheumatol (1998) 37(12):1324–1329.
  • WEBER SM, CHEN JM, LEVITZ SM: Inhibition of mitogen-activated protein kinase signaling by chloroquine. Immunol (2002) 168(10):5303–5309.
  • JEONG JY, CHOI JW, JEON KI, JUE DM: Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology (2002) 105(1):83–91.
  • GENESTIER L, PAILLOT R, FOURNEL S, FERRARO C, MIOSSEC P, REVILLARD JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. Clin. Invest. (1998) 102(2):322–328.
  • NAKAZAWA F, MATSUNO H, YUDOH K et al.: Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. Rheumatol (2001) 28(8):1800–1808.
  • BREEDVELD FC, DAYER JM: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. D AK (2000) 59(11):841–849.
  • MANNA SK, MUKHOPADHYAY A, AGGARWAL BB: Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. Immunol (2000) 165(10):5962–5969.
  • LAMPA J, KLARESKOG L, RONNELID J: Effects of gold on cytokine production in vitro; increase of monocyte dependent interleukin 10 production and decrease of interferon-gamma levels. J. Rheumatol (2002) 29(1):21–28.
  • KIM TS, KANG BY, LEE MH, CHOE YK, HWANG SY: Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Thl to the Th2 pathway. Br. J. Pharmacol (2001) 134(3):571–578.
  • WEBER CK, LIPTAY S, WIRTH T, ADLER G, SCHMID RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology (2000) 119(5):1209–1218.
  • HASKO G, SZABO C, NEMETH ZH, DEITCH EA: Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology (2001) 103(4):473–478.
  • SYLVESTER J, LIACINI A, LI WQ, DEHNADE F, ZAFARULLAH M: Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-kappaB activities. Ma Pharmacol (2001) 59(5):1196–1205.
  • LIN N, SATOT, ITO A:Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts. Arthritic Rheum. (2001) 44(9):2193–2200.
  • HOMMES D, VAN DEN BLINK B, PLASSE T et al: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology (2002) 122(1):7–14.
  • SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med (1991) 173(3):699–703.
  • OLIVER SJ, FREEMAN SL, CORRAL LG,OCAMPO CJ, KAPLAN G: Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin. Exp. Immunol (1999) 118(2):315–321.
  • MARRIOTT JB, WESTBYM, COOKSON S et al.: CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. Immunol (1998) 161(8):4236–4243.
  • LA MAESTRA L, ZANINONI A, MARRIOTT JB, LAZZARIN A, DALGLEISH AG, BARCELLINI W: The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNE-alpha) expression in acutely and chronically infected cells M vitro. Clin. Exp. Immunol (2000) 119(1):123–129.
  • MARRIOTT JB, MULLER G, STIRLING D, DALGLEISH AG: Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin. Biol. Ther. (2001) 1(4):675–682.
  • CAMPBELL IK, O'DONNELL K, LAWLOR KE, WICKS IP: Severe inflammatory arthritis and lymphadenopathy in the absence ofTNF.j Clin. Invest. (2001) 107(12):1519–1527.
  • VAN DEN BERG WB: Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin. Arthritic Rheum. (2001) 30(5 Suppl. 2):7-i6. Review.
  • LUBBERTS E, JOOSTEN LA, OPPERS B et al.: IL- 1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. Immunol (2001) 167(2):1004–1013.
  • LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl. I Med. (2000) 343(22):1594–1602.
  • BATHON JM, MARTIN RW, FLEISCHMANN RIVI et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl. Med. (2000) 343(22):1586–1593.
  • AUPPERLE K, BENNETT B, HAN Z, BOYLE D, MANNING A, FIRESTEIN G: NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. Immunol (2001) 166(4):2705–2711.
  • TAK PP, GERLAG DM, AUPPERLE KR et al.: Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritic Rheum. (2001) 44(8):1897–1907.
  • OJO-AMAIZE EA, KAPAHI P, KAKKANAIAH VN et al.: Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IkappaB kinase. hranunol. (2001) 209 (2) :149–157.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.